Walter M. Stadler to Patient Selection
This is a "connection" page, showing publications Walter M. Stadler has written about Patient Selection.
Connection Strength
0.545
-
Enrollment Barriers for Molecular Targeted Trials. JAMA Oncol. 2023 06 01; 9(6):863-864.
Score: 0.172
-
A trial postmortem: challenges in conducting a randomized, double-blind, phase 2 study in men with castration-resistant prostate cancer. Eur Urol. 2012 Nov; 62(5):864-6.
Score: 0.082
-
Randomized phase II trials: a long-term investment with promising returns. J Natl Cancer Inst. 2011 Jul 20; 103(14):1093-100.
Score: 0.075
-
The HLA-A2-restricted PSMA peptide LLHETDSAV is poorly immunogenic in patients with metastatic prostate cancer. Prostate. 2009 Feb 01; 69(2):142-8.
Score: 0.064
-
Developing drugs that do not cause tumor regression. Clin Adv Hematol Oncol. 2003 Nov; 1(11):654-5.
Score: 0.044
-
Study of cohort-specific consent and patient control in phase I cancer trials. J Clin Oncol. 1998 Jul; 16(7):2305-12.
Score: 0.031
-
Analyzing the clinical actionability of germline pharmacogenomic findings in oncology. Cancer. 2018 07 15; 124(14):3052-3065.
Score: 0.030
-
Evaluation of the prostate bed for local recurrence after radical prostatectomy using endorectal magnetic resonance imaging. Int J Radiat Oncol Biol Phys. 2013 Feb 01; 85(2):378-84.
Score: 0.020
-
Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia. Gynecol Oncol. 2008 Jul; 110(1):49-55.
Score: 0.015
-
Long-term follow-up of nonmyeloablative allogeneic stem cell transplantation for renal cell carcinoma: The University of Chicago Experience. Bone Marrow Transplant. 2005 Feb; 35(3):253-60.
Score: 0.012